Faith L. Charles
Faith L. Charles's purchase track record
Faith L. Charles has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/18/2026 | CNSP | $34K | +15.7% | pending | — |
| 4/26/2024 | ABEO | $25K | +56.4% | +99.4% | +13.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Abeona Reports ZEVASKYN Launch Momentum and Revenue Growth. Abeona Therapeutics highlighted positive momentum for its ZEVASKYN product launch and revenue growth during a recent H.C. Wainwright event. The company is also expanding its distribution network as the treatment for RDEB gains traction. These developments provide fundamental context for the stock, which is currently trading near its 52-week low.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
CDT Highlights Sarborg Quantum Computing IP for Drug Discovery. CDT announced that it is focusing on Sarborg's expanding quantum computing intellectual property and its application to drug discovery. The company was also mentioned among health‑care stocks that moved in Friday's session, showing recent market attention. The stock is currently near a long‑standing support level, which may be observed as the company pursues these initiatives.
Transaction History
| CNSP | ▲ Buy | Open Market | 7,100 | $34K | 5/18/2026 | View on chart |
| ABEO | ▲ Buy | Grant | 37,313 | $0 | 1/26/2026 | View on chart |
| ABEO | ▼ Sell | Open Market | 10,738 | $63K | 7/9/2025 | View on chart |
| CDT | ▲ Buy | Grant | 115,194 | $100K | 4/16/2025 | View on chart |
| CDT | ▲ Buy | Grant | 46,629 | $41K | 3/30/2025 | View on chart |
| ABEO | ▲ Buy | Grant | 36,101 | $0 | 1/31/2025 | View on chart |
| CDT | ▲ Buy | Grant | 266,594 | $24K | 11/18/2024 | View on chart |
| CDT | ▲ Buy | Grant | 75,000 | — | 11/18/2024 | View on chart |
| ABEO | ▲ Buy | Grant | 11,797 | $0 | 8/26/2024 | View on chart |
| ABEO | ▲ Buy | Grant | 23,611 | $0 | 7/8/2024 | View on chart |
| ABEO | ▲ Buy | Open Market | 7,550 | $25K | 4/26/2024 | View on chart |
| ABEO | ▼ Sell | Open Market | 8,330 | $41K | 9/27/2023 | View on chart |
| ABEO | ▲ Buy | Grant | 58,689 | $271K | 6/14/2023 | View on chart |
| ABEO | ▲ Buy | Grant | 13,400 | $0 | 9/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CNS Pharmaceuticals Holds Shareholder/Analyst Call
On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.
CNS Pharmaceuticals Holds Shareholder/Analyst Call. On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.